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Introduction 
Mesenchymal stromal cells (MSC) play a crucial role in tissue homeostasis
whereby they control inflammation and regulate stem cell renewal and differenti-
ation. Their immunomodulatory properties, which target both adaptive and innate
immune responses, have been extensively documented in vitro and in vivo.1-7
Although the underlying mechanisms are only partially known, it is widely accept-
ed that the combination of soluble factors and contact-dependent interactions
plays a fundamental role. Upregulation of inducible nitric oxide synthase (iNOS or
NOS2), one of the key MSC transcriptional responses resulting in the secretion of
a short-lived molecule with potent immunomodulatory effects, nitric oxide (NO),8,9
is not sufficient in itself to explain MSC the immunosuppressive activities. In fact,
one of the main MSC effector mechanisms is the recruitment and functional mod-
ulation of myeloid cells, such as inflammatory monocytes and tissue
macrophages.6,10-14
MSC also contribute to the hematopoietic stem cell (HSC) niche in which they reg-
ulate hematopoietic cell number and differentiation.15,16 These properties have been
harnessed therapeutically to promote hematopoietic regeneration. However, early in
vivo animal studies have not been unequivocally confirmed by clinical investiga-
tions.18,19 Although the mechanisms by which MSC regulate HSC are still unknown,
it is arguable that, resembling what has been described for their immunosuppressive
actions, MSC require other cells to execute their functions.20 In particular, a few stud-
ies have described that the interaction between MSC and bone marrow (BM)
macrophages contributes to the retention of HSC in the BM21 and prevents their
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ABSTRACT
exhaustion.20-24 The nature of this interaction has not, how-
ever, been elucidated.
In this work, we have tested the hypothesis that MSC
may skew the differentiation and expansion of BM
myeloid progenitors with the ability to accelerate
hematopoietic reconstitution. We have observed that
MSC selectively promote the expansion and differentia-
tion of CD11b+ cells from the BM and that this function is
largely dependent on NOS2. Ex-vivo generated MSC-
induced CD11b+ cells exhibit the ability to accelerate
hematopoietic engraftment and reconstitution.
Methods
Cell cultures and media
Murine BM MSC were generated from crushed femora and tib-
iae of wild type (WT) C57Bl/6 or Nos2-/- mice (for further informa-
tion, see the Online Supplementary Appendix). Human BM MSC
were generated from human BM mononuclear cells (MNC). All
samples were collected after informed consent had been obtained
in accordance with Ethics Committee approval from the Province
of Monza-Brianza (Italy) (approval date: 16 Oct 2014, approval file
name: BM-NICHE). Further details on the methods used to gener-
ate murine and human MSC, and on the generation of MSC-
induced myeloid cells, are presented in the Online Supplementary
Appendix.  
Flow cytometry
Unspecific binding sites were blocked with phosphate-buffered
saline supplemented with 1% fetal bovine serum and either Fc
blocker (CD16/32, eBioscience) or whole mouse IgG (Sigma
Aldrich) before cells were incubated with the respective mono-
clonal antibody at 4°C for 30 min. After incubation, cells were
washed twice with phosphate-buffered saline and analyzed by
flow cytometry with a BD FACSCalibur, BD FACS CantoII, BD
LSRII or BD Fortessa (BD Biosciences, NJ, USA). Data were subse-
quently analyzed using FlowJo software (Oregon, USA). A com-
plete list of antibodies used is given in the Online Supplementary
Appendix. 
In vivo experiments 
For the adoptive transfer of MSC, sublethally irradiated (split
dose of 800 cGy) WT CD45.1 C57Bl/6 recipients were transplant-
ed by tail vein injection with 2x106 BM cells and 0.2x106 WT or
Nos2-/- MSC 4 h after the second dose of irradiation. Mice were
sacrificed after 13 days and spleens and BM analyzed by FACS. 
For the adoptive transfer of CD11b+ cells, sublethally irradiated
(split dose of 800 cGy) WT CD45.1 C57Bl/6 recipients were trans-
planted with 5x104 BM cells alone or with 2x106 CD45.2+ MSC-
induced CD11b+ cells 4 h after the second dose of irradiation.
Peripheral blood samples were taken every 2 weeks after the
transplant up to 4 months. Peripheral blood was lysed with lysis
buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM EDTA, pH 7.3),
and cells were stained for flow cytometry.
Statistical analysis
Data were analyzed using GraphPad Prism Software. An
unpaired two-tailed Student t-test was run with a confidence inter-
val of 95%, and expressed as mean ± standard error of the mean
(SEM) or standard deviation (SD). For analysis of three groups of
data, one-way analysis of variance with Bonferroni’s multiple
comparison test was used, and expressed as mean ± SEM.
Results
Mesenchymal stromal cells induce the expansion and
differentiation of CD11b+ cells from bone marrow
myeloid progenitors
Unfractionated BM MNC were cultured in the presence
MSC induce regenerative myeloid cells
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Figure 1. Mesenchymal stromal cells
induce the differentiation of bone marrow
mononuclear cells into myeloid cells. BM
MNC were cultured alone or with MSC (ratio
5:1) for 4 days. (A) Proportion of CD11b+Gr-
1high and CD11b+Gr-1low-neg cells in the live
gate. A typical result of ten independently
performed experiments is shown. (B)
Percentage of Gr-1high and Gr-1low-neg cells in
CD11b+ cells. Mean of ten independent
experiments, ± SEM. *** P<0.001 ****
P<0.0001 unpaired t test. (C) Absolute num-
ber of CD11b+ cells recovered from initial
seeding from BM cultured alone (white bars)
or with MSC (black bars) for 4 days. Mean of
ten independent experiments, ± SEM
**P<0.005, unpaired t test.
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or absence of MSC. After 4 days, cultures were analyzed
for the expression of the myeloid markers CD11b and Gr-
125 (Figure 1A). Whilst in the control cultures the vast
majority of BM cells consisted of CD11b+Gr-1high, in those
with MSC there was a marked skew towards the forma-
tion of a large proportion of CD11b+Gr-1low-neg (50.6% ±
3.9%) (Figure 1B). Analysis of absolute cell numbers
revealed that the presence of MSC could not only main-
tain the survival of total CD11b+ cells as compared to BM
MNC cultured alone (5.7x106 ± 1.8x106 compared to
1.7x106 ±1.4x106) (Figure 1C), but also drive a selective
retention and/or expansion of the Gr-1low-neg population.
At morphological analysis the MSC-induced CD11b+
myeloid cells consisted of a fairly homogeneous popula-
tion of large cells with reniform nuclei and abundant pale
vacuolated cytoplasm with granules (Figure 2A). The
immunophenotype of CD11b+ sorted cells revealed a 6-
fold increase in F4/80+ (36.5%±10.3%), a 3-fold increase in
IL4Rα+ (18.2%±7.5%), and a 2-fold increase in CD169+
(2.3%±0.6%) cells when compared to BM MNC cultured
alone (Figure 2B, left panel). BM MNC cultured with MSC
also expressed CD115 (48.6%±12.4%), CD206
(20.6%±2%) and CD68 (16.5%±4.9%) (Figure 2B, left
panel). These macrophage markers were expressed only in
the Gr-1low-neg subset (Figure 2B, right panel), whilst CD115
was detected both in the Gr-1high and the Gr-1low-neg subsets.
To understand the target cells of MSC-induced myeloid
differentiation, FACS-sorted HSC, common myeloid pro-
genitors (CMP) or granulocyte/macrophage progenitors
(GMP) were cultured with MSC. Megakaryocyte/ery-
throid progenitors (MEP) and unfractionated BM MNC
were used as negative or positive control of differentia-
tion, respectively. MSC induced the differentiation of only
CMP and GMP into CD11b+Gr-1high and CD11b+Gr-1low-neg
cells, with no effect on HSC or MEP (Figure 3A). The pro-
portion of Gr-1low-neg cells from CMP cultures was higher
than in the cultures with unfractionated BM (Gr-1low-neg:
60.1% ± 8.9% versus 35% ± 12.8% in unfractionated
BM+MSC) (Figure 3B), and, accordingly, a 2-fold increase
in the percentage of CD11b+F4/80+ cells (63.6% ± 9.8%
versus 36.8% ± 13.7% in BM+MSC) and a higher percent-
age of CD11b+CD115+ cells (85.8% ± 1.3% versus 38.6% ±
18.9% in BM+MSC) (Figure 3C). 
Mesenchymal stromal cell-induced CD11b+ Gr-1low-neg
formation is Nos2-dependent
Since NOS2 is one of the key effector molecules in MSC
immunomodulatory properties,8,9 we tested the hypothe-
sis that it could also be fundamental for the generation of
Gr-1low-neg cells. The differentiation of CD11b+Gr-1low-neg cells
was significantly impaired in cultures with Nos2-/- MSC
(16.6% ± 1.2% versus 30.8% ± 2.5% in BM+MSC WT),
which correlated with an increased proportion in
CD11b+Gr-1high cells (82.3% ± 1.2% versus 68.2% ± 2.2%
in BM+MSC WT) (Figure 4A,B). Nos2-/- BM cells did not
affect the ability of MSC to induce the generation of
CD11b+Gr-1low-neg cells (Figure 4A).
Mesenchymal stromal cells increase macrophage 
formation during hematopoietic reconstitution
The ability of MSC to drive the expansion and differen-
tiation of CD11b+ cells was then studied in vivo.
Sublethally irradiated mice were transplanted with BM
cells from a congenic (CD45.1+) donor either alone or with
WT or Nos2-/- MSC. The proportion of the donor myeloid
C. Trento et al.
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Figure 2. Mesenchymal stromal cell-induced CD11b+ cells consist of a large
proportion of M0 macrophages. (A) May-Grünwald Giemsa staining of cytospin
preparations of CD11b+ cells isolated from BM MNC cultured with MSC for 4
days. (B) BM MNC cultured alone or with MSC for 4 days were evaluated for the
expression of macrophage surface markers within the CD11b+ gated popula-
tion (open histograms) against their matched isotype controls (filled his-
tograms). Contour plots within the CD11b+ gated population show the expres-
sion of each surface marker versus Gr-1 expression in BM MNC cultured with
MSC. Contour and histograms plots from one out of six independent experi-
ments, and mean fluorescence intensity values presented as mean ± SD of six
independent experiments. *P<0.05, **P<0.01, ***P<0.001, unpaired t test,
all comparisons between ‘BM’ versus ‘BM+MSC’. 
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B
populations was analyzed in the BM and spleens of recip-
ient mice 13 days after the transplant. At this time-point
there was no difference in CD45.1+ engraftment (Figure
5A). However, the proportion and absolute numbers of
Gr-1negF4/80+SSClow macrophages were increased in mice
receiving BM and WT MSC compared to the control
group (3.2%±0.3% versus 1.44%±0.18%; absolute num-
ber: 0.46x106±0.12x106 versus 0.16x106±0.06x106) (Figure
5B,C). An increase in the proportion (Figure 5D) but not in
the absolute number (Online Supplementary Figure S4E) of
Ly6G-Ly6C+ monocytes was found in the WT MSC-treat-
ed group (23.5%±1.9% versus 16.9%±1.5%; absolute
number: 1.06x106±0.14x106 versus 0.96x106±0.25x106).
Confirming in vitro results, the adoptive transfer of Nos2-
/- MSC failed to increase the proportion and absolute num-
ber of CD11b+Gr-1negF4/80+SSClow macrophages and the
proportion of Ly6G-Ly6C+ monocytes within the donor
CD45.1+ engraftment (Gr-1negF4/80+SSClow macrophages:
2.1%±0.26% BM+Nos2-/- MSC; absolute number:
0.32x106±0.07x106 BM+Nos2-/- MSC. Ly6G-Ly6C+ mono-
cytes: 18.1%±1.3% BM+Nos2-/- MSC) (Figure 5B-D). 
There was no difference in the proportion or absolute
number of neutrophils or eosinophils in the donor engraft-
ment in all treated groups (Online Supplementary Figure
S4C,D). The adoptive transfer of MSC and BM did not
affect hematopoietic generation of donor myeloid cells in
the spleen of recipient mice (data not shown). 
Ex-vivo mesenchymal stromal cell-induced CD11b+
cells accelerate hematopoietic reconstitution
In order to further characterize the role of MSC-induced
CD11b+ cells in vivo, we investigated their effect on
hematopoietic reconstitution. For this purpose, sublethally
irradiated mice received a BM transplant from a congenic
donor with or without CD11b+ cells purified from the
BM-MSC co-cultures. The engraftment of donor cells was
monitored in the peripheral blood every 2 weeks. The
group given CD11b+ cells showed a higher proportion
(11.7%±1.5% versus 20.9%±2.1%) and absolute number
(17.0±4.2 versus 43.3±7.5 CD45.1+ leukocytes/mL) of donor
cells as compared to the control group already at 2 weeks.
Such an increment was also observed in each leukocyte
compartment (neutrophils: 37.4%±3.4% versus
53.3%±2.9%, and 8.4±2.4 versus 22.8±3.8 CD45.1+ neu-
trophils/mL; monocytes: 16.4%±2.4 versus 21.2%±2.9%,
and 4.9±1.2 versus 12.1±2.9 CD45.1+ monocytes/mL,
P=0.0195; B lymphocytes: 10.7%±1.5% versus
18.2%±2.4%, and 3.9±0.7 versus 9.3±2.7 CD45.1+ B lym-
phocytes/mL; T lymphocytes: 0.06%±0.03% versus
0.3%±0.09%, and 0.02±0.01 versus 0.1±0.04 CD45.1+ T
lymphocytes/mL) (Figure 6A,B).
Analysis of the absolute numbers of leukocyte popula-
tions in peripheral blood showed that CD11b+ cells not
only expanded donor engraftment but they also enhanced
the recovery of total hematopoiesis. At 2 weeks, the group
MSC induce regenerative myeloid cells
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Figure 3. Mesenchymal stromal cell-induced CD11b+ differentiation targets committed myeloid progenitors but not hematopoietic stem cells. Unfractionated BM
MNC (BM+MSC) or sorted CMP (CMP+MSC), GMP (GMP+MSC), MEP (MEP+MSC) and HSC (HSC+MSC) were cultured with MSC for 4 days. (A) Proportion of CD11b+Gr-
1high and CD11b+Gr-1low-neg cells in the live gate. A typical result of four independently performed experiments is shown. (B) Percentage of Gr-1high and Gr-1low-neg cells
within CD11b+ cells from BM, CMP or GMP cultures with MSC. Mean of four independent experiments, ± SEM. *P<0.05 unpaired t test. (C) Percentage of F4/80+
and CD115+ cells within the CD11b+ gate. Mean of four independent experiments, ± SEM *P<0.05, unpaired t test. 
B C
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of mice given CD11b+ cells showed higher absolute counts
of neutrophils (15.2±3.4 versus 42.1±5.9 neutrophils/mL), B
lymphocytes (27.8±4.8 versus 51.5±7.7 B lymphocytes/mL)
and monocytes (22.6±3.7 versus 37.9±4.1 monocytes/mL)
(Online Supplementary Figure S5A). 
Monitoring of the hematopoietic engraftment at later
stages revealed that the CD11b+-driven hematopoietic
reconstitution was still evident 4 weeks after the trans-
plant (Online Supplementary Figures S5B and S6A,B). At 6
weeks the enhancement effect was selectively observed
within the B and T lymphocytes compartments, whilst no
difference in the quality and quantity of engraftment was
found from 8 weeks onwards (Online Supplementary Figures
S5B and S6A,B). 
Human mesenchymal stromal cells induce 
the differentiation of CD14+ cells from bone marrow
mononuclear cells
Finally, we asked whether the newly discovered ability
of murine MSC to induce macrophage differentiation is
also a property of human MSC. For this purpose, human
BM MNC were cultured alone or with human MSC for 7
C. Trento et al.
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Figure 4. Mesenchymal stromal cell-induced myeloid cell formation is
Nos2-dependent. (A, B) BM MNC isolated from WT or Nos2-/- mice were
cultured with MSC isolated from WT or Nos2-/- mice for 4 days. (A)
Contour plots represent CD11b+Gr-1high and CD11b+Gr-1low-neg propor-
tions in the live gate. A typical result of three independently performed
experiments is shown. (B) Percentages of Gr-1high and Gr-1low-neg within
the CD11b+ gate. Mean of three independent experiments ±SEM,
**P<0.01, unpaired t test.
Figure 5. Adoptive transfer of mesenchy-
mal stromal cells increases macrophage
formation during hematopoietic reconstitu-
tion. Sublethally irradiated (800 cGy)
CD45.2 WT recipients were injected with
2x106 CD45.1 WT BM cells, either alone
(BM – white bars) or in combination with
0.2x106 CD45.2 WT MSC (BM+WT MSC –
black bars) or 0.2x106 CD45.2 Nos2-/- MSC
(BM+Nos2-/- MSC – gray bars). 13 days after
the transfer, BM and spleen were analyzed
by FACS. (A) Percentage of donor engraft-
ment in BM and spleen. (B, C) Percentage
(B) and absolute number (C) of Gr-
1negF4/80+SSClow macrophages within donor
hematopoiesis (CD45.1+ cells) in the BM.
Mean of three independent experiments
±SEM, *P<0.05, **P<0.01 One-way analy-
sis of variance (ANOVA) with the Bonferroni
multiple comparison test. (D) Percentage of
Ly6G-Ly6C+ monocytes within donor
hematopoiesis (CD45.1+ cells) in the BM.
Mean of three independent experiments
±SEM, **P<0.01 One-way ANOVA with the
Bonferroni multiple comparison test.  
BA
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days. We decided to analyze the proportions of CD14+,
CD14+HLA-DRlow-neg and CD14+CD16+ cells, which best
represent total myeloid population, macrophages and
non-classical monocytes, respectively. The presence of
human MSC induced an increment in CD14+ cells with a
selective effect on non-classical monocytes (CD14+:
15.5%±2.2% versus 25.8%±3.6%, in human BM and
human BM cultured with human MSC, respectively;
CD14+CD16+: 2.2%±0.6% versus 7.5%±1.6%, in human
BM and human BM cultured with human MSC, respective-
ly) (Figure 7A). The analysis of the absolute numbers within
the CD45+ population confirmed the statistically significant
increase in non-classical monocytes (CD14+CD16+:
0.01x106±0.003x106 versus 0.08x106±0.03x106 in human BM
and human BM cultured with human MSC, respectively)
(Figure 7B). In contrast to what we observed in the murine
system, the addition of the NOS2 inhibitor 1400W to cul-
tures did not affect myeloid differentiation (data not
shown).
Discussion
Our study unveils a previously unknown property of
BM MSC consisting in the ability to differentiate and
expand in vitro and in vivo myeloid cells from BM progeni-
tors. Importantly, the administration of these myeloid
cells accelerates hematopoietic reconstitution in BM trans-
plant recipients. 
The mechanism by which MSC promote myeloid
expansion is largely dependent on NOS2. Although NOS2
MSC induce regenerative myeloid cells
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Figure 6. Adoptive transfer of mesenchymal stromal cell-induced CD11b+ cells accelerates engraftment. Sublethally irradiated (800 cGy) CD45.2 WT recipients
were injected with 5x104 CD45.1 WT BM cells, either alone (BM) or in combination with 2x106 MSC-induced CD11b+ cells (BM+CD11b+). Peripheral blood samples
were taken 14 days after the transplant, and the frequency of donor hematopoiesis analyzed by FACS as described in the Methods. (A) Frequency of donor
hematopoiesis in MNC, T cells (CD3+), B cells (CD19+), monocytes (Gr-1negCD115+) and neutrophils (Gr-1highCD115+). Mean of four independent experiments ± SEM,
**P<0.01, ***P<0.001, unpaired t test. (B) Absolute number of donor hematopoietic cells in MNC, T cells (CD3+), B cells (CD19+), monocytes (Gr-1negCD115+) and
neutrophils (Gr-1highCD115+). Mean of four independent experiments ±SEM, *P<0.05, **P<0.01, unpaired t test.
BA
Figure 7. Human mesenchymal stromal cells induce the differentiation of
human bone marrow mononuclear cells into myeloid cells. Human BM MNC
were cultured alone or with MSC (ratio 10:1). After 7 days, the percentages (A)
and absolute numbers (B) of CD14+, CD14+HLA-DRlow-neg and CD14+CD16+ in the
CD45+ population were analyzed. Mean of six independent experiments, ± SEM.
*P<0.05, unpaired t test.
A
B
has been extensively identified as the main effector mech-
anism accounting for MSC immunosuppressive activity
and similarly implicated in myeloid immunobiology, this
is the first study that attributes NOS2 the ability to differ-
entiate and expand myeloid cells and macrophages. In
contrast to the MSC-mediated immunosuppressive activi-
ty,8 we observed that the generation and expansion of
myeloid cells was not influenced by inflammatory mole-
cules such as tumor necrosis factor-α and interferon-γ (data
not shown). This suggests that, despite using similar mech-
anisms, MSC-induced myeloid differentiation occurs
independently of inflammation.
The potent ability of myeloid cells expanded ex-vivo by
MSC to accelerate hematopoietic regeneration has at least
two implications. The first is that the role of MSC in reg-
ulating HSC differentiation is not exclusively a direct one
but can also be exerted by recruiting accessory cells. This
has already been documented in the landscape of MSC
immunomodulation.26 Furthermore, the regenerative prop-
erties on the hematopoietic system may apply to other tis-
sues. The molecular and functional profile of MSC-educat-
ed myeloid cells recapitulates that of the resident
macrophages which have been described as involved in
tissue repair activity in other organs.27,28 Therefore, our
data might lend support to the notion that stroma/fibrob-
lasts orchestrate tissue homeostasis.
The second set of implications affects the clinical
approach to the use of MSC. MSC have long been studied
for their ability to promote hematopoietic engraftment
based on the evidence that they are a crucial component of
the stem cell niche. After the initial investigation in xeno-
geneic models showing that MSC co-transplanted with
umbilical cord blood CD34+ cells resulted in an increase in
BM engraftment,17 subsequent studies indicated that such
engraftment is only transient.29,30 Similar confounding fac-
tors can be found in clinical studies in pediatric31,32 and
adult19,33-35 cohorts with small and heterogeneous groups of
patients. If MSC graft facilitating activity is the consequence
of inducing BM progenitors to differentiate into regenera-
tive myeloid cells, the variability in clinical outcome may
result from the content of progenitors in the original donor
inoculum rather than the actual direct activity of MSC on
HSC differentiation.
Our data highlight the complexity of the MSC ‘clinical
niche effect’. Although the adoptive transfer of MSC at the
time of BM transplantation significantly increased the per-
centage and number of donor macrophages in the BM
(Figure 5B,C), we could not observe a consequent incre-
ment in the overall donor hematopoietic engraftment
(Figure 5A). This discrepancy could be explained by the low
number of macrophages produced by the MSC infusion. In
fact, when BM cells were infused with a high number of ex-
vivo MSC-induced myeloid cells, the hematopoietic engraft-
ment was greatly enhanced (Figure 6).
The crucial role of myeloid cells in facilitating engraft-
ment is also supported by recent clinical evidence in which
MSC have been used to condition cord blood HSC ex-vivo
in order to accelerate hematopoietic recovery. Our data
shed light on the interpretation of these successful clinical
results.36 In that study, the MSC-conditioned cord blood
unit did not engraft, indicating it mainly played a facilitating
effect on the engraftment of the co-transplanted unmanip-
ulated unit. Our study suggests that the graft facilitating
effect might have been mediated by MSC-expanded mono-
cytes, as confirmed by the phenotypic analysis of their
MSC-educated cord blood HSC. Therefore, we propose the
intriguing possibility that ex-vivo MSC induced myeloid
cells could be harnessed in the clinical setting to expedite
hematopoietic recovery and immune reconstitution in high-
risk transplantation procedures.37
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